从特有种紫菀中分离的两个新木质素属

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-04-22 DOI:10.1016/j.phytol.2025.102961

Yancho Zarev , Preslav Enchev , Rositsa Mihaylova , Georgi Momekov , Luc Pieters , Hans Michler , Iliana Ionkova

{"title":"从特有种紫菀中分离的两个新木质素属","authors":"Yancho Zarev , Preslav Enchev , Rositsa Mihaylova , Georgi Momekov , Luc Pieters , Hans Michler , Iliana Ionkova","doi":"10.1016/j.phytol.2025.102961","DOIUrl":null,"url":null,"abstract":"<div><div>Four compounds, a lignan 1, including two new neolignans 2 and 3, and one pterocarpan 4, were isolated from the arial parts of endemic Bulgarian species Astracantha aitosensis (syn. Astragalus aitosensis) (Ivan.) Fabaceae by means of conventional separation methods. The structure of those compounds was elucidated by means of spectroscopic methods, including 1D and 2D NMR, as well as HRESI-MS. Among the isolated compounds is a new neolignan (2) named astracandioxin and a new dihydrobenzofuran (3) named astracanamide, while for the maackiain-3-O-β-D-glucoside (4) this is the first report of isolation from the genus and for syringaresinol-4-O-β-D-glucoside (1) first report of isolation from A. aitosensis, respectively. The antiproliferative activity of the isolated compounds was assessed in a panel of human tumor cell lines of different origin.</div></div>","PeriodicalId":20408,"journal":{"name":"Phytochemistry Letters","volume":"67 ","pages":"Article 102961"},"PeriodicalIF":1.3000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Two new neolignans isolated from the endemic species Astracantha aitosensis\",\"authors\":\"Yancho Zarev , Preslav Enchev , Rositsa Mihaylova , Georgi Momekov , Luc Pieters , Hans Michler , Iliana Ionkova\",\"doi\":\"10.1016/j.phytol.2025.102961\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Four compounds, a lignan 1, including two new neolignans 2 and 3, and one pterocarpan 4, were isolated from the arial parts of endemic Bulgarian species Astracantha aitosensis (syn. Astragalus aitosensis) (Ivan.) Fabaceae by means of conventional separation methods. The structure of those compounds was elucidated by means of spectroscopic methods, including 1D and 2D NMR, as well as HRESI-MS. Among the isolated compounds is a new neolignan (2) named astracandioxin and a new dihydrobenzofuran (3) named astracanamide, while for the maackiain-3-O-β-D-glucoside (4) this is the first report of isolation from the genus and for syringaresinol-4-O-β-D-glucoside (1) first report of isolation from A. aitosensis, respectively. The antiproliferative activity of the isolated compounds was assessed in a panel of human tumor cell lines of different origin.</div></div>\",\"PeriodicalId\":20408,\"journal\":{\"name\":\"Phytochemistry Letters\",\"volume\":\"67 \",\"pages\":\"Article 102961\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Phytochemistry Letters\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S187439002501050X\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytochemistry Letters","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S187439002501050X","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

从保加利亚特有种aitosensis Astracantha aitosensis（同. Astragalus aitosensis）的arial部分分离到木脂素1（包括2个新木脂素2和3）和1个翼木素4 (pterocarpan 4) 4个化合物。采用常规分离方法分离豆科植物。这些化合物的结构通过波谱方法，包括1D和2D NMR以及HRESI-MS进行了鉴定。其中新分离的木脂素(2)命名为astracandioxin，新分离的二氢苯并呋喃(3)命名为astracanamide， maackiain-3-O-β-D-glucoside(4)为首次从该属中分离得到，丁香精醇-4- o -β-D-glucoside(1)为首次从aitosensis中分离得到。在一组不同来源的人类肿瘤细胞系中评估了分离化合物的抗增殖活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Two new neolignans isolated from the endemic species Astracantha aitosensis

Four compounds, a lignan 1, including two new neolignans 2 and 3, and one pterocarpan 4, were isolated from the arial parts of endemic Bulgarian species Astracantha aitosensis (syn. Astragalus aitosensis) (Ivan.) Fabaceae by means of conventional separation methods. The structure of those compounds was elucidated by means of spectroscopic methods, including 1D and 2D NMR, as well as HRESI-MS. Among the isolated compounds is a new neolignan (2) named astracandioxin and a new dihydrobenzofuran (3) named astracanamide, while for the maackiain-3-O-β-D-glucoside (4) this is the first report of isolation from the genus and for syringaresinol-4-O-β-D-glucoside (1) first report of isolation from A. aitosensis, respectively. The antiproliferative activity of the isolated compounds was assessed in a panel of human tumor cell lines of different origin.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.